SCA
EBS icon

Stonebridge Capital Advisors’s Emergent Biosolutions EBS Stock Holding History

Stonebridge Capital Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-310
Closed -$13K – 941
2022
Q1 		$13K Buy
+310
New +$13.7K ﹤0.01% 619

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stonebridge Capital Advisors's EBS Position: Q2 2022 in Review

Stonebridge Capital Advisors sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 310 shares — an estimated $13K sold.

Stonebridge Capital Advisors first reported a position in EBS in Q1 2022 and held it in 1 quarter. The position peaked at $13K in Q1 2022. 232 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

  • Stonebridge Capital Advisors reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 310 Emergent Biosolutions shares in Q2 2022, an estimated $13K.
  • Stonebridge Capital Advisors first reported a position in Emergent Biosolutions in Q1 2022 and held it in 1 quarter.
  • Stonebridge Capital Advisors's Emergent Biosolutions position peaked at $13K in Q1 2022.
  • 232 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.